Eisai Gets Canadian Approval For Banzel Epilepsy Drug
This article was originally published in PharmAsia News
Executive Summary
Eisai said its Banzel (rufinamide) drug has received Canadian approval for treating Lennox-Gastaut Syndrome, considered one of the most severe and rarest forms of epilepsy